» Articles » PMID: 7082992

A Post-mortem Study of the Cholinergic and GABA Systems in Senile Dementia

Overview
Journal Brain
Specialty Neurology
Date 1982 Jun 1
PMID 7082992
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Choline acetyltransferase (ChAT) activity and gamma-aminobutyric acid (GABA) concentration were measured in 19 cerebral cortical areas and 22 subcortical areas of brains from 26 control and 25 histologically proven cases of Alzheimer's disease. Reduced ChAt activity was observed in all the cortical areas examined in the Alzheimer cases dying before the median age of 79 years. In the Alzheimer cases aged greater than 79 years at death, 7 out of the 9 frontal cortical areas had a normal ChAT activity when compared with controls. Significant reductions in GABA concentrations in the Alzheimer cases were confined to the temporal cortex. Significant reductions in ChAT activity in subcortical areas were confined to 8 of the 22 regions examined. Notably these included the septal nuclei and substantia innominata, the proposed origins of the cholinergic projections to the hippocampus and neocortex, respectively. There were no reductions in GABA concentrations outside the cerebral cortex. Four multi-infarct cases and 6 cases with normal histology were found to have a small reduction in ChAT activity confined to only a few areas. The data are consistent with a predominant loss in Alzheimer's disease of the diffuse cholinergic projection from the brainstem and basal forebrain.

Citing Articles

Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?.

Zhang S, Lu J, Jin Z, Xu H, Zhang D, Chen J Front Pharmacol. 2024; 15:1459655.

PMID: 39355779 PMC: 11442227. DOI: 10.3389/fphar.2024.1459655.


Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease.

Li J, Haj Ebrahimi A, Ali A Int J Mol Sci. 2024; 25(10).

PMID: 38791206 PMC: 11121252. DOI: 10.3390/ijms25105169.


Gray matter gamma-hydroxy-butyric acid and glutamate reflect beta-amyloid burden at old age.

Schreiner S, Van Bergen J, Gietl A, Buck A, Hock C, Pruessmann K Alzheimers Dement (Amst). 2024; 16(2):e12587.

PMID: 38690510 PMC: 11058481. DOI: 10.1002/dad2.12587.


The Unveiling of Therapeutic Targets for Alzheimer's Disease: An Integrative Review.

Madar P, Nagalapur P, Chaudhari S, Sharma D, Koparde A, Buchade R Curr Top Med Chem. 2024; 24(10):850-868.

PMID: 38424435 DOI: 10.2174/0115680266282492240220101049.


Voltage-Gated Na Channels in Alzheimer's Disease: Physiological Roles and Therapeutic Potential.

Baumgartner T, Haghighijoo Z, Goode N, Dvorak N, Arman P, Laezza F Life (Basel). 2023; 13(8).

PMID: 37629512 PMC: 10455313. DOI: 10.3390/life13081655.